Overview

Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERD

Status:
Completed
Trial end date:
2020-02-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Ilaprazole 20 mg in patients with non-erosive reflux disease. This study intends to demonstrate the clinical superiority of Ilaprazole 20 mg to placebo administered once daily for 4 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Il-Yang Pharm. Co., Ltd.